CapsulesClinical Overview
Thalidomide Capsules (50mg, 100mg, 200mg) is the prototypical immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3, and suppresses tumor necrosis factor-alpha (TNF-alpha) synthesis while inhibiting basic fibroblast growth factor (bFGF) and VEGF-induced angiogenesis. Indicated in combination with dexamethasone for newly diagnosed multiple myeloma and for acute treatment and maintenance of erythema nodosum leprosum (ENL / Hansen's disease).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with water, preferably at bedtime at least 1 hour after dinner to mitigate profound sedative effects. Swallow capsules whole. Complete pregnancy testing prior to dispensing. Co-administer prophylactic anticoagulation.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Somnolence/sedation, profound constipation, dizziness, peripheral neuropathy (symmetric painful paresthesias, often irreversible), tremor, edema. Rare/Severe: Catastrophic phocomelia (amelia, phocomelia, internal organ defects), venous thromboembolism (DVT/PE), bradycardia, and Stevens-Johnson syndrome.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe life-threatening teratogenicity / phocomelia; absolute contraindication in pregnancy; strict pregnancy prevention program and two forms of contraception required. Black Box Warning: Venous thromboembolism; mandatory anticoagulation. Causes irreversible peripheral neuropathy; monitor closely and discontinue at early signs of sensory loss.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.
Thalidomide Capsules 100mg
Thalidomide Capsules (50mg, 100mg, 200mg) is the prototypical immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3, and suppresses tumor necrosis factor-alpha (TNF-alpha) synthesis while inhibiting basic fibroblast growth factor (bFGF) and VEGF-induced angiogenesis. Indicated in combination with dexamethasone for newly diagnosed multiple myeloma and for acute treatment and maintenance of erythema nodosum leprosum (ENL / Hansen's disease).
Thalidomide Capsules 200mg
Thalidomide Capsules (50mg, 100mg, 200mg) is the prototypical immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3, and suppresses tumor necrosis factor-alpha (TNF-alpha) synthesis while inhibiting basic fibroblast growth factor (bFGF) and VEGF-induced angiogenesis. Indicated in combination with dexamethasone for newly diagnosed multiple myeloma and for acute treatment and maintenance of erythema nodosum leprosum (ENL / Hansen's disease).